|
| 36658128 | Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. | Nat Commun | 2023 |
| 36210483 | Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019. | Clin Infect Dis | 2023 |
| 36265696 | Alterations of gray and white matter volumes and cortical thickness in treated HIV-positive patients. | Magnetic Resonance Imaging | 2023 |
| 37745410 | Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. | bioRxiv | 2023 |
| 37650237 | Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial. | J Infect Dis | 2023 |
| 37650236 | Long COVID After Bamlanivimab Treatment. | J Infect Dis | 2023 |
| 37650234 | Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. | J Infect Dis | 2023 |
| 37650232 | Immune Status and SARS-CoV-2 Viral Dynamics. | J Infect Dis | 2023 |
| 37650233 | Variant-Specific Viral Kinetics in Acute COVID-19. | J Infect Dis | 2023 |
| 37650231 | ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. | J Infect Dis | 2023 |
| 37650230 | Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19. | J Infect Dis | 2023 |
| 37401993 | Adherence to Antiretrovirals and HIV Viral Suppression Under COVID-19 Pandemic Interruption - Findings from a Randomized Clinical Trial Using Ingestible Sensors to Monitor Adherence. | AIDS Behav | 2023 |
| 37279602 | One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial. | Clin Infect Dis | 2023 |
| 36773626 | Need for clear inclusion criteria in reviews of antiretroviral treatments - Authors' reply. | Lancet HIV | 2023 |
| 37072885 | Zinc and Coronavirus Disease 2019. | Clin Infect Dis | 2023 |
| 37068272 | Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. | Ann Intern Med | 2023 |
| 36802755 | Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. | Ann Intern Med | 2023 |
| 37183889 | Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus. | Clin Infect Dis | 2023 |
| 36540980 | Leveraging Multi-Ancestry Polygenic Risk Scores for Body Mass Index to Predict Antiretroviral Therapy-Induced Weight Gain. | Pac Symp Biocomput | 2023 |
| 36601684 | Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials. | Clin Transl Sci | 2023 |
| 36661240 | Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19. | J Infect Dis | 2023 |
| 37099295 | Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. | JAMA Netw Open | 2023 |
| 36467293 | Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19. | Open Forum Infect Dis | 2022 |
| 36372731 | Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial. | EBioMedicine | 2022 |
| 36309038 | Two-drug regimens for HIV treatment. | Lancet HIV | 2022 |
| 35966031 | Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19. | | 2022 |
| 35995785 | Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. | Nat Commun | 2022 |
| 35793677 | Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. | Cell Rep Med | 2022 |
| 35982660 | Viral and Symptom Rebound in Untreated COVID-19 Infection. | medRxiv | 2022 |
| 36378539 | Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. | JCI Insight | 2022 |
| 35466963 | High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. | AIDS | 2022 |
| 36714798 | A community-partnered approach for diversity in COVID-19 vaccine clinical trials. | J Clin Transl Sci | 2022 |
| 34587382 | Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. | N Engl J Med | 2021 |
| 33901188 | Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. | PLoS Genet | 2021 |
| 32569355 | Initiation of Antiretroviral Therapy in the Hospital Is Associated With Linkage to Human Immunodeficiency Virus (HIV) Care for Persons Living With HIV and Substance Use Disorder. | Clinical Infectious Diseases | 2021 |
| 32829410 | Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. | Clin Infect Dis | 2021 |
| 34981077 | Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial. | medRxiv | 2021 |
| 35018382 | Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. | medRxiv | 2021 |
| 34379922 | Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. | N Engl J Med | 2021 |
| 34545376 | Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy. | medRxiv | 2021 |
| 31536156 | Real-Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-Encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study. | Clin Transl Sci | 2020 |
| 32645158 | Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. | J Infect Dis | 2020 |
| 32566285 | Perceptions of People Living with HIV and HIV Healthcare Providers on Real-Time Measuring and Monitoring of Antiretroviral Adherence Using Ingestible Sensors: A Qualitative Study. | AIDS Res Treat | 2020 |
| 32612233 | Clinical targeting of HIV capsid protein with a long-acting small molecule. | Nature | 2020 |
| 31516025 | Pharmacokinetics of Coencapsulated Antiretrovirals with Ingestible Sensors. | AIDS Res Hum Retroviruses | 2020 |
| 31159715 | Viral suppression and HIV transmission behaviors among hospitalized patients living with HIV. | International Journal of STD and AIDS | 2019 |
| 30219823 | Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. | Clin Infect Dis | 2019 |
| 29920584 | The North-South Divide: Substance Use Risk, Care Engagement, and Viral Suppression Among Hospitalized Human Immunodeficiency Virus-Infected Patients in 11 US Cities. | Clin Infect Dis | 2019 |
| 30531304 | Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. | J Acquir Immune Defic Syndr | 2019 |
| 30334877 | Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. | J Acquir Immune Defic Syndr | 2019 |